Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

Brief summary (registry, in English)

This study is a treatment protocol with blinatumomab for infants under 1 year old who are diagnosed with acute lymphoblastic leukemia with a specific unfavorable genetic alteration. The purpose of the study is to improve the outcome of this disease in infants.

What you commit to

• Study type: Interventional · Phase 3
• Planned participants: 160
• From 15 Dec 2022 to the primary completion date, Sept 2027
• 168 sites in 25 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 1 day to 1 year · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (168)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Related publications

• Immunotherapy in B-Cell Acute Lymphoblastic Leukemia.J Natl Compr Canc Netw · 2025 · PMID 41671463